+41 91 682 20 40 info@elixi-int.com

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/10/TECENTRIQ_Logo.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
Roche – Tecentriq

Roche – Tecentriq

FDA approves Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for people with a specific type of metastatic lung cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved TECENTRIQ® (atezolizumab) for the treatment of people with metastatic non-small cell…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/10/logo_expopharm.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
ELIXI In Expopharm 2016

ELIXI in Expopharm 2016

The expopharm is the largest pharmaceutical trade fair in Europe: Many key decision-makers from all sectors of the industry anywhere else  would here. The current major manufacturers present their latest innovations in the industry, the leading software companies present the…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/10/zykadia.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
Novartis ALK+ Metastatic NSCLC Therapy Zykadia® Extends Progression-free Survival Beyond 18 Months In Phase II Study

Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study

Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in ALKi-naïve patients with brain metastases at baseline, per blinded independent review committee…

Read More

Warning: getimagesize(/home/elixitom/public_html/wp-content/uploads/2016/10/IMG_4089.jpg): failed to open stream: No such file or directory in /home/clients/5f0b4deb973bf941571734948687755e/web/elixi/wp-content/themes/Total/framework/classes/image-resize.php on line 116
Pfizer Receives Positive CHMP Opinion For IBRANCE – Metastatic Breast Cancer In Europe

Pfizer Receives Positive CHMP Opinion For IBRANCE – Metastatic Breast Cancer In Europe

Pfizer Inc. (NYSE:PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that IBRANCE® (palbociclib) be granted marketing authorization in the European Union (EU) for the…

Read More